Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients.

Onco Targets Ther · 2017 · PMC5644603 · PMID 29066917

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP =0.001actually significant

25 Furthermore, Morris et al in a randomized trial reported highly significant ( P =0.001) improvement in the BDFS in patients treated by ADT for 12 months with elective pelvic irradiation and boosted by low dose rate brachytherapy to the prostate compared with those boosted by external beam for total radiation dose of 78 Gy to the prostate.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.